Target- |
MechanismImmunostimulants |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase 3, Observer blind, Randomized, Active-Controlled Trial Evaluating the Immunologic Non-inferiority, Safety and Tolerability of a 15-valent Pneumococcal Conjugate Vaccine Compared to a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given in a Reduced Dosing Schedule with Routine Pediatric Vaccinations. - NA
A Phase 3, Observer blind, Randomized, Active-Controlled Trial Evaluating the Immunologic Non-inferiority, Safety and Tolerability of a 15-valent Pneumococcal Conjugate Vaccine Compared to a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given with Routine Pediatric Vaccinations. - NA
A Multi-Centre, Open label, Randomized (1:1), Parallel, Phase II Study to evaluate the Safety, Tolerability and Immunogenicity of a 15-Valent Pneumococcal Conjugate Vaccine (PCV15) in healthy subjects between 2-5 years of age (Group I: 15-Valent Pneumococcal Conjugate Vaccine, Group II: Prevnar 13®).
100 Clinical Results associated with Tergene Biotech Pvt Ltd.
0 Patents (Medical) associated with Tergene Biotech Pvt Ltd.
100 Deals associated with Tergene Biotech Pvt Ltd.
100 Translational Medicine associated with Tergene Biotech Pvt Ltd.